CPI-613 (Devimistat) in Combination With Chemoradiation in Patients With Pancreatic Adenocarcinoma

Phase 1 Terminated 8 enrolled Medical College of Wisconsin Barbara Ann Karmanos Cancer Institute · collab Cornerstone Pharmaceuticals · collab

Non-randomizedSequentialOpen-labelTreatment

Summary

This is a single-center, open-label, phase I study designed to determine the maximum tolerated dose (MTD) and safety profile of CPI-613® when used concomitantly with chemoradiation for local control of pancreatic adenocarcinoma (PDAC).

Timeline

Start: 2022-10-31
Primary completion: 2025-07-08
Completion: 2025-07-08

Publications

Khan HY, Kamgar M, Aboukameel A, Bannoura S, Chung BY, Li Y, Hallak MNA, Philip PA, Tsai S, Luther S, Hall WA, Azmi AS. Targeting Cellular Metabolism With CPI-613 Sensitizes Pancreatic Cancer Cells to Radiation Therapy. Adv Radiat Oncol. 2022 Nov 9;8(1):101122. doi: 10.1016/j.adro.2022.101122. eCollection 2023 Jan-Feb.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	CPI-613	Small molecule	250 mg/m2	Intravenous
Subject	CPI-613	Small molecule	500 mg/m2	Intravenous
Subject	CPI-613	Small molecule	1000 mg/m2	Intravenous
Subject	CPI-613	Small molecule	1500 mg/m2	Intravenous
Background	Gemcitabine	Small molecule	400 mg/m2	Intravenous

CPI-613 (Devimistat) in Combination With Chemoradiation in Patients With Pancreatic Adenocarcinoma

Summary

Timeline

Publications

Drugs

Indications